Lawsuits against Pfizer alleging that its blockbuster cholesterol drug Lipitor (atorvastatin) – a statin taken by millions of Americans – caused Type 2 diabetes continue to mount, as the first bellwether cases in federal multidistrict litigation (MDL) move closer to trial.
According to the latest report from the U.S. Judicial Panel on Multidistrict Litigation, more than 2,400 cases are pending before Judge Richard M. Gergel in the United States District Court for The District of South Carolina, Charleston Division. Plaintiffs assert that they developed Type 2 diabetes after taking Lipitor and must now face additional health risks and loss of quality of life.
